TCGA-55-8510-01A-11R-2403-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 55
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8392886 | — | cohortA1 | 0.952 |
| 2 | TCGA-55-8619-01A-11R-2403-07 | — | cohortA1 | 0.943 |
| 3 | SRR598894 | GTEX | — | 0.939 |
| 4 | SRR6013478 | — | cohortMD2 | 0.931 |
| 5 | TCGA-38-A44F-01A-11R-A24H-07 | — | cohortA1 | 0.930 |
| 6 | SRR1394297 | GTEX | — | 0.930 |
| 7 | SRR1331289 | GTEX | — | 0.930 |
| 8 | SRR1468141 | GTEX | — | 0.930 |
| 9 | TCGA-86-8671-01A-11R-2403-07 | — | cohortMD2 | 0.929 |
| 10 | TCGA-99-AA5R-01A-11R-A39D-07 | — | cohortA1 | 0.927 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.370 | Inavolisib | — uncovered |
| MYOGENESIS | 0.360 | Inavolisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.330 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.270 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| APOPTOSIS | 0.060 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.050 | Inavolisib | — uncovered |